Vabysmo 6mg Injection

Vabysmo 6mg Injection contains the active ingredient Faricimab, a humanised bispecific antibody that targets and inhibits two pathways: VEGF-A and Ang-2. This mechanism reduces fluid accumulation, controls abnormal blood vessel growth, and stabilises retinal health. Vabysmo 6mg Injection is indicated for the treatment of Diabetic Macular Oedema (DME), Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularisation (mCNV), conditions that cause significant vision problems. Vabysmo 6mg Injection improves vision by addressing these underlying pathological processes and promoting retinal stability.

Administration of Vabysmo 6mg Injection must be performed by a healthcare professional in a controlled clinical setting. Serious risks associated with use include eye infections, retinal detachment, increased intraocular pressure, and thromboembolic events, potentially leading to stroke or myocardial infarction. The dosage and treatment schedule will be determined by your healthcare provider based on your individual clinical condition. Regular monitoring and follow-up appointments are essential to assess therapeutic response and manage any adverse effects. Patients who are pregnant, breastfeeding, or planning pregnancy should inform their healthcare provider before commencing treatment with Vabysmo 6mg Injection.

Vabysmo 6mg Injection treats the following eye conditions: Diabetic macular edema (DME) Wet age-related macular degeneration (AMD) Retinal vein occlusion (RVO) Myopic choroidal neovascularisation (mCNV)

Vabysmo 6mg Injection is a humanised bispecific antibody that targets VEGF-A and Ang-2. It suppresses endothelial cell growth and vascular permeability by binding to VEGF-A while promoting vascular stability and reducing sensitivity to VEGF-A by targeting Ang-2. The role of Ang-2 inhibition in treating nAMD and DME is not yet fully understood.

Vabysmo 6mg Injection should be administered in a healthcare setting, typically by an eye care specialist. The dose will be determined by the doctor based on the specific condition being treated. It is given through an intravitreal injection (injection into the eye), and the treatment schedule may vary depending on the patient's condition and response to therapy. Always follow the doctor's instructions for dosing and administration.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Common Side Effects of Vabysmo 6mg Injection are: Conjunctival hemorrhage Vitreous floaters Retinal pigment epithelial tear Increased intraocular pressure & inflammation Eye pain & Ocular discomfort Vitreous haemorrhage Serious Side Effects of Vabysmo 6mg Injection are: Corneal abrasion Eye pruritus & Increased lacrimation Ocular hyperemia Blurred vision & Eye irritation The sensation of a foreign body in the eye Endophthalmitis Retinal tear Rhegmatogenous retinal detachment

Vabysmo 6mg Injection can cause serious eye infections, retinal detachment, and temporary increases in eye pressure. It may also raise the risk of blood clots, especially in the first year. Your healthcare provider will decide the dosage and schedule, and a trained professional will administer the Vabysmo 6mg Injection in a healthcare setting. Always consult your doctor before starting or adjusting treatment, particularly if you are pregnant, breastfeeding, or of reproductive potential.